[Effects of cinepazide maleate injection on blood pressure in patients with acute ischemic stroke and hypertension]. To investigate the blood pressure change in patients with acute ischemic stroke (AIS) and hypertension treated with cinepazide maleate injection. This was a subgroup analysis of post-marketing clinical confirmation study of cinepazide maleate injection for acute ischemic stroke : a randomized, double-blinded, multicenter, placebo-parallel controlled trial, which conducted in China from August 2016 to February 2019. Eligible patients fulfilled the inclusive criteria of acute anterior circulation ischemic stroke with National Institutes of Health Stroke Scale (NIHSS) scores of 7-25. The primary endpoints were mean blood pressure of AIS patients treated with cinepazide maleate
Effect of Cinepazide Maleate on Serum Inflammatory Factors of ICU Patients with Severe Cerebral Hemorrhage after Surgery. To explore the effect of cinepazide maleate on serum inflammatory factors of intensive care unit (ICU) patients with severe cerebral hemorrhage after surgery. 116 ICU patients with severe cerebral hemorrhage treated in Taian Maternal and Child Health Hospital from June 2018 to June 2020 were selected as the research objects and randomly divided into the control group and experimental group, with 58 patients in each group. The control group was given routine treatment, while the experimental group was additionally given an intravenous drip of cinepazide maleate to compare the clinical efficacy and serum inflammatory factors between the two groups. The total effective rate
Efficacy and safety of cinepazide maleate injection in patients with acute ischemic stroke: a multicenter, randomized, double-blind, placebo-controlled trial. Ischemic stroke is a leading cause of morbidity and mortality. Thrombolytic therapy improves disability and survival rates; however, to be effective, it must be given within 4.5 h of onset. Moreover, thrombolytic therapy is frequently contraindicated. Therefore, alternative therapeutic options are required. In China, cinepazide maleate injection has been shown to improve the cerebral collateral circulation and further reduce disability in stroke patients; however, very few studies investigating this therapy have been conducted to date. Therefore, this study aimed to further confirm the efficacy and safety of cinepazide maleate injection
Assessment of the Efficacy and Safety of Cinepazide on Stroke Based on Chinese Population: A Systematic Review and Meta-Analysis. PROSPEROInternational prospective register of systematic reviews Print | PDFAssessment of the Efficacy and Safety of Cinepazide on Stroke Based on Chinese Population: A Systematic Review and Meta-Analysis.Zou Yingying, Sun Weitong, shikai chen, tinghui liu, yi here.CitationZou Yingying, Sun Weitong, shikai chen, tinghui liu, yi zhang. Assessment of the Efficacy and Safety of Cinepazide on Stroke Based on Chinese Population: A Systematic Review and Meta-Analysis.. PROSPERO 2022 CRD42022363933 Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022363933Review questionP: patients with stroke.I: CinepazideC: placebo, typical therapy, etc.O
Clinical Study of Cinepazide Maleate Injection in the Treatment of Acute Ischemic Stroke This is a multicenter, randomized, double-blind, placebo-controlled, parallel controlled, post marketing confirmatory clinical trial in Chinese patients with acute ischemic stroke. Objective to evaluate the efficacy and safety of cinepazide maleate injection compared with placebo in the treatment of patients ) and will be randomly assigned to the experimental group (cinepazide maleate injection group) or the control group (placebo group).During the treatment period, all subjects will receive cinepazide maleate injection or placebo by intravenous drip at the rate of 100ml / h, once a day for 14 consecutive days. During the treatment, all subjects need to receive basic treatment: citicoline sodium injection 0.5g, dissolved
group (n = 43) and control group (n = 40). All of the patients underwent emergency or elective PCI. Patients in the control group were treated with mannitol to reduce intracranial pressure and cinepazide maleate to improve microcirculation in the brain as well as given a comprehensive treatment with oxygen inhalation, fluid infusion, acid-base imbalance correction and electrolyte disturbance. Patients
treatment group were treated firstly with Barbecue reposition maneuver and then were given Alprostadil, Cinepazide and Betahistine drug treatment. Both groups were evaluated after 7 days and 28 days treatment, and the recurrence rate was analyzed after 3 months. After 7 days of the treatment , the recovery rate of the two groups was 62.5% and 73.3%, respectively. There's no significant difference between
, multicenter clinical study of mildronate injection for treating acute cerebral infarction. 113 patients in the experimental group received mildronate injection, and 114 patients in the active-control group received cinepazide injection. In addition, both groups were given aspirin as a basic treatment. Modified Rankin Scale (mRS) score was performed at 2 weeks and 3 months after treatment. National is as effective and safe as cinepazide injection in treating acute cerebral infarction.
drugs associated with a significant risk were pyrithyldione, cinepazide, aprindine hydrochloride, carbamazepine, sulfonamides, phenytoin and phenytoin sodium, beta-lactam antibiotics, erythromycin stearate and erythromycin ethylsuccinate, and diclofenac sodium. Individual attributable incidences for all these drugs, which collectively accounted for 68.6% of cases, were less than 1:1 million per year
Post-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World Study Post-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World Study - Full Text View - ClinicalTrials.gov Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort. Hide glossary GlossaryStudy record managers: refer to the Data Element Definitions if submitting studies (100).Please remove one or more studies before adding more. Post-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World Study (PACER) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details
Methanesulfonic Acid Cinepazide Injection for Treatment of Acute Cerebral Infarction Methanesulfonic Acid Cinepazide Injection for Treatment of Acute Cerebral Infarction - Full Text View - ClinicalTrials.gov Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort. Hide glossary GlossaryStudy record managers: refer to the Data Element Definitions if submitting studies (100).Please remove one or more studies before adding more. Methanesulfonic Acid Cinepazide Injection for Treatment of Acute Cerebral Infarction The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. ClinicalTrials.gov
: cinepazide maleate injection Drug: aspirin Phase 2 Detailed Description: A randomized, double-blind, multi-center clinical study was made on mildronate injection for treating acute cerebral infarction. 113 cases in the experimental group were given with mildronate injection, while 114 cases in the active-control group were given with cinepazide maleate injection. In addition, both groups were given Drug: mildronate injectionOther Name: infusion of mildronate infusion of mildronate(500mg) once a day and for 14 da Drug: aspirinOther Name: infusion of aspirin (100mg) once a day for days Active Comparator: cinepazide maleateinfusion of cinepazide maleate Drug: cinepazide maleate